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Antibody binding to the icosahedral arrange-
ment of envelope proteins on the surface of
flaviviruses can result in neutralization or en-
hancement of infection. We evaluated how
many antibodies must bind to a given epitope
on West Nile virus (WNV) to achieve neutraliza-
tion. The most potent monoclonal antibodies
(mAbs) block infection at concentrations that
result in low occupancy of accessible sites on
the virion, with neutralization occurring when
as few as 30 of 180 envelope proteins are
bound. In contrast, weakly neutralizing mAbs
recognize fewer sites on the virion and require
almost complete occupancy to inhibit WNV in-
fection. For all mAbs studied, enhancement of
infection is possible in cells bearing activating
Fc-g receptors when the number of mAbs
docked to the virion is not sufficient for neutral-
ization. Thus, neutralization is best described
by amodel requiring ‘‘multiple hits’’ with the cu-
mulative functional outcome determined by in-
terplay between antibody affinity and epitope
accessibility.
INTRODUCTION
West Nile virus (WNV) is a single-stranded positive-sense
RNA virus of the Flavivirus genus. The 11 kb WNV geno-
mic RNA is translated in the cytoplasm as a polyprotein
and then cleaved into three structural (capsid [C], pre-
membrane/membrane [prM/M], and envelope [E]) and
seven nonstructural proteins by virus- and host-encoded
proteases (Brinton, 2002; Lindenbach and Rice, 2001).
In nature,WNV ismaintained in an enzootic cycle between
mosquitoes and birds but can also infect and cause dis-
ease in humans, horses, and other vertebrate animals (re-Cellviewed in Hayes et al., 2005). WNV infection of humans is
associated with a febrile illness that can progress to lethal
encephalitis, particularly in the elderly and immunocom-
promised (Ceausu et al., 1997; Petersen et al., 2002; Sej-
var et al., 2003). Since the mid-1990s, outbreaks of WNV
fever and encephalitis have occurred annually throughout
the world (Dauphin et al., 2004). Following its introduction
into the United States in 1999, WNV rapidly disseminated
across North America and has now been reported in
Mexico, South America, and the Caribbean (Deardorff
et al., 2006; Komar and Clark, 2006; Lanciotti et al.,
1999). At present, treatment is supportive, and no vaccine
or therapy exists for human use.
Humoral immunity is an essential aspect of host protec-
tion against WNV (Ben-Nathan et al., 2003; Camenga
et al., 1974; Diamond et al., 2003a, 2003b; Oliphant
et al., 2005; Tesh et al., 2002; Wang et al., 2001) and other
flaviviruses (Roehrig et al., 2001). B cell-deficient mice die
after WNV infection but are protected by passive transfer
of immune sera (Diamond et al., 2003a, 2003b). Antibody-
mediated control of flavivirus infection in vivo (Ben-Nathan
et al., 2003; Diamond et al., 2003a, 2003b; Engle and
Diamond, 2003; Gould et al., 2005; Oliphant et al., 2005)
has been correlated with in vitro neutralizing activity (Kauf-
man et al., 1987; Phillpotts et al., 1987; Roehrig et al.,
2001). The majority of neutralizing antibodies against flavi-
viruses are directed against the E protein, although some
likely recognize the prM/M protein (Colombage et al.,
1998; Falconar, 1999; Pincus et al., 1992; Vazquez et al.,
2002).
The crystal structure of the E protein ectodomain has
been solved for several flaviviruses including dengue virus
(DENV), tick-borne encephalitis virus (TBEV), and WNV
(Kanai et al., 2006; Modis et al., 2004, 2005; Nybakken
et al., 2006; Rey et al., 1995; Zhang et al., 2004). E is com-
posed of three domains that mediate viral attachment, en-
try, and assembly. Domain III (DIII) contains the putative
receptor-binding domain (Bhardwaj et al., 2001; Chu
et al., 2005), domain II (DII) encodes the putative fusion
loop involved in pH-dependent fusion of virus and host
cell membranes (Allison et al., 2001), and domain I (DI)Host & Microbe 1, 135–145, April 2007 ª2007 Elsevier Inc. 135
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WNV DIII
(A) Ribbon diagram of the DIII portion of the
WNV E protein as viewed down the long axis
of the E protein monomer. Residues that com-
prise antibody-binding determinants are indi-
cated.
(B) Surface representation diagrams of DIII in-
dicating the binding determinants for the six
mAbs studied. Red color indicates residues
that, when mutated, abrogate 100% of mAb
binding as measured by a quantitative yeast
mapping method. Yellow color identifies resi-
dues that result in greater than 50% reduction
in mAb binding.
(C) Molecular modeling of epitope accessibility
on the WNV virion. Residues that form the epi-
tope for each antibody studied were previously
identified using yeast-display technology. Res-
idues involved in binding for mAb E9, E16, E22,
and E49 (4.0 A˚ radius magenta atoms) were
mapped onto the crystal structure of the E pro-
tein and then docked onto the pseudoatomic
model of the mature WNV virion. mAbs E24
and E47 bind an epitope that overlaps the
E16 epitope. Virions are depicted as 2.0 A˚
radius Ca atoms colored according to the sym-
metry axis to which they are closest, 2-fold
(cyan), 3-fold (green), and 5-fold (yellow).participates in E protein structural rearrangements re-
quired for fusion (reviewed in Mukhopadhyay et al.,
2005). Crystallography, NMR, and epitope mapping stud-
ies have established that E protein-specific neutralizing
antibodies map to all three domains of the WNV E protein
(Beasley and Barrett, 2002; Nybakken et al., 2005;
Oliphant et al., 2005, 2006; Sanchez et al., 2005; Volk
et al., 2004). The most potent inhibitory antibodies recog-
nize a single neutralizing epitope on the upper lateral face
of DIII that constitute the amino-terminal region and three
loops of the immunoglobulin-like fold (Beasley and Bar-
rett, 2002; Oliphant et al., 2005; Sanchez et al., 2005;
Volk et al., 2004). Recent studies in rodent models of
WNV infection demonstrate that antibodies that bind this
DIII epitope are protective or therapeutic when passively
administered (Morrey et al., 2006; Oliphant et al., 2005).
The structure of theWNV virion has been determined by
cryoelectron microscopy (Kuhn et al., 2002; Mukho-
padhyay et al., 2003). The mature WNV is an icosahedral
particle that lacks conventional T = 3 symmetry (reviewed
in Mukhopadhyay et al., 2005). As a result, the E protein
exists in three chemically distinct environments (shown
in Figure 1C). Crystallographic modeling and cryoelectron
microscopy studies have shown that only 120 of the avail-
able 180 E protein epitopes can be occupied by the DIII-
specific neutralizing antibody E16 due to steric hindrance
of binding of the 60 DIII epitopes that lie closest to the
5-fold symmetry axis (shown in yellow in Figure 1C) (Kauf-
mann et al., 2006; Nybakken et al., 2005). These studies
provide a structural demonstration that the accessibility
of an epitope is determined in part by its location on the
surface of the virion and suggest that engagement of all136 Cell Host & Microbe 1, 135–145, April 2007 ª2007 Elseviethe E proteins on the virion is not a requirement for neutral-
ization. In this study, we evaluate how the number of
antibodies bound to DIII-specific epitopes on flaviviruses
impacts the infectivity of the virus particle.
RESULTS
The stoichiometric requirements of antibody-mediated
neutralization of WNV infection were investigated using
monoclonal antibodies (mAbs) that bind epitopes on DIII
of the E protein. A group of six DIII-reactive murine
mAbs were selected from a recently described panel pro-
duced by immunization with purified recombinant E pro-
tein or infectious WNV (Oliphant et al., 2005). Epitope
mapping data for each antibody have been reported and
were used as part of our selection criteria to include
mAbs with a variety of functional properties and binding
specificities (Oliphant et al., 2005) (Figures 1A and 1B
and Table 1).
To investigate the relative accessibility of each epitope
on the virion, molecular modeling studies were performed
in which residues that comprise the epitope of each anti-
body were mapped onto the E protein crystal structure
and modeled on the pseudoatomic reconstruction of the
matureWNV virion (Figure 1C). This approach predicts no-
ticeable differences in the accessibility of several of the
antibody epitopes. E16, E24, E47, and E49 bind determi-
nants on the upper lateral surface of DIII that project away
from the surface of the virion, whereas the residues bound
by E22 and E9 are found on lateral surfaces partially ob-
scured by neighboring E proteins. Moreover, while ther Inc.
Cell Host & Microbe
Neutralization and ADE of WNV InfectionTable 1. Neutralization Potency and Avidity of DIII-Specific WNV mAbs
EC50 (nM) Standard Deviation (nM) Slope Standard Deviation na Avidity (nM) Standard Deviation (nM) nb
E9 39.5 25.5 0.35 0.07 4 2.33 0.94 9
E16 0.043 0.016 2.09 0.41 15 0.15 0.08 22
E22 1.39 0.9 0.34 0.02 6 1.02 0.081 3
E24 0.018 0.011 1.01 0.2 10 0.1 0.07 12
E47 0.031 0.015 0.8 0.12 5 0.26 0.2 9
E49 0.98 0.85 0.61 0.06 6 1.07 0.65 9
aNumber of replicates for the neutralization studies.
bNumber of replicates for the affinity measurements.residues constituting the E16 epitope are solvent exposed
in all three different symmetry environments, steric con-
straints prevent simultaneous occupancy of more than
120 sites on the virion (Kaufmann et al., 2006; Nybakken
et al., 2006). Thus, this modeling approach predicts the
upper limit for occupancy at each epitope on the mature
virion. A more quantitative assessment of the number of
antibodies that bind the E9, E22, and E49 epitopes under
saturating conditions awaits further structural studies.
Antibody-Mediated Neutralization
The neutralization potency of each DIII-specific antibody
was characterized using a validated highly quantitative
approach (Pierson et al., 2006). Reporter virus particles
(RVP) are virus-like particles composed of the structural
proteins of WNV and a subgenomic replicon encoding
a reporter gene. RVPs are capable of only a single round
of infection and allow virus infection to be measured as
a function of reporter gene activity. An important feature
of this approach is that the functional outcome of antibody
engagement is measured under conditions that satisfy the
law of mass action as it applies to virus neutralization, in-
creasing precision and accuracy (Andrewes and Elford,
1933; Klasse and Sattentau, 2002; Pierson et al., 2006).
In this study, neutralization experiments were performed
primarily using a B-lymphoblastoid cell line that stably
expresses the attachment factor DC-SIGNR (CD209L)
(Davis et al., 2006b).CelNeutralization profiles for each antibody were gener-
ated using 19 2-fold dilutions of antibody performed in
triplicate (Figure 2A). The potency of each antibody was
calculated using a curve-fitting approach and expressed
as the concentration that inhibits 50% of infection
(EC50). Analysis of dose-response curves obtained from
each antibody revealed a wide range in neutralization ac-
tivity (Table 1). As predicted from preliminary studies per-
formed using the traditional plaque reduction neutraliza-
tion test (PRNT50) (Oliphant et al., 2005), antibodies that
bind an overlapping cluster of residues on an upper lateral
ridge of DIII centered around residues 307 and 332 were
the most potent and could neutralize infection at concen-
trations as low as 20 pM (Figure 2A and Table 1). In con-
trast, the two antibodies that bind lateral surfaces on DIII
(E22 and E9) inhibit infection only at much higher concen-
trations (Figures 2A and 2B and Table 1).
In addition to contributing to the precision of our mea-
surements, the use of a large number of data points also
provides insight into the nature of the interactions that re-
sult in neutralization (Figure 2A). Differences in the shapes
of the dose-response curves among the antibodies stud-
ied were observed. Dose-response profiles of the most
potently neutralizing antibodies (E16, E24, and E47) were
relatively steep when compared to the relatively flat
shape of the neutralization profile of less potent mAbs
such as E9 (Table 1). The steepness of these profiles in-
dicates a greater capacity to neutralize virus at lowerFigure 2. Neutralization of WNV by
DIII-Specific mAbs
(A) Nineteen dilutions of each mAb were incu-
bated with WNV RVPs and used to infect Raji
cells that express the c-type lectin DC-SIGNR.
Infection was monitored as a function of GFP
expression using flow cytometry. Error bars
display the standard error of triplicate infec-
tions (present even when not visible due to
low variation), while dotted lines illustrate the
95% confidence interval. Nonlinear regression
analysis was used to calculate the EC50.
(B) Identification of a neutralization-resistant fraction of WNV. Dose-response curves with mAb E22 do not extend to the x axis, revealing a population
of RVPs that are resistant to E22-mediated neutralization at high concentrations of antibody. Shown is the regression analysis describing the neu-
tralization potency of E22 focusing only on the fraction of RVPs that can be neutralized by mAb. Error bars display the standard error of triplicate
infections, while dashed lines illustrate the 95% confidence interval. Nonlinear regression analysis was used to calculate the EC50. Considering
the entire RVP population (including the 31% of virions in the resistant fraction) reveals a significantly less potent response (2 nM).l Host & Microbe 1, 135–145, April 2007 ª2007 Elsevier Inc. 137
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between Neutralization and ADE of
WNV Infection
(A–D) (A) Complexes of mAb E47 and WNV
RVPs were formed by incubation at room tem-
perature and divided into three aliquots for ad-
dition to Raji-R (red circles), K562 (green cir-
cles), or K562-R cells (blue circles). Error bars
display the standard error of triplicate infec-
tions, while dashed lines illustrate the 95%
confidence interval. Nonlinear regression anal-
ysis was used to calculate the EC50, revealing
a potency of 47.6 pM (95%CL: 40–56.4 pM) on
Raji-R cells. For K562 and K562-R cells, the
presence of ADE prevents analysis of antibody
potency using curve-fitting approaches. Addi-
tional dose-response curves of mAbs E9 (B),
E22 (C), and E49 (D) were also performed using
Raji-R and K562 cells as described above.
(E and F) To determine the impact of decreas-
ing the strength of the antibody-virion interac-
tion on both neutralization and ADE, RVPs
were produced that incorporate either a wild-
type E protein (E), or a T3301 variant (F), and
used in neutralization studies on Raji-R and
K562 cells with mAb E24.concentrations of antibody and reflects differences in the
fraction of epitopes on the virion that must be bound by
antibody for neutralization to occur (discussed below).
We also noted that not all virions in the population were
equally sensitive to neutralization by mAbs. Inspection of
the dose-response curves performed with the mAb E22
indicates that approximately 31% (±8%, n = 6) of the vi-
rions were insensitive to neutralization at even the highest
concentrations of antibody tested (Figure 2B). As a result,
calculating the concentration of this antibody required to
completely neutralize infection with confidence may not
be possible (greater than 2 nM). In contrast, if only those
particles sensitive to E22-mediated neutralization are
considered, the EC50 of this antibody is much lower
(0.29 nM± 0.07, n = 6). As RVPs are produced by transfec-
tion of DNA plasmids and are thus identical with respect to
E protein sequence, this finding suggests that heteroge-
neity exists with respect to the accessibility of the E22
epitope in the RVP population.
Relationships between Antibody-Dependent
Neutralization and Enhancement of Infection
Under some circumstances, the engagement of Flavivirus
virions by antibody facilitates the infection of Fc-g or com-
plement receptor-expressing cell lines in vitro. Both pro-
cesses are thought to reflect an opsonic phenomenon
by which the efficiency of virus attachment is augmented
in the presence of antibody and/or complement, respec-
tively. Antibody-dependent enhancement of infection
(ADE) has been suggested to contribute to the pathogen-
esis of secondary DENV infections (reviewed in Halstead,
2003) and is implicated in the adverse effects following138 Cell Host & Microbe 1, 135–145, April 2007 ª2007 Elseviechallenge of individuals vaccinated with some formalin-
inactivated vaccines (Barrett and Gould, 1986; Gould and
Buckley, 1989), including measles and respiratory syncy-
tial viruses (Polack et al., 2002). To explore the quantitative
relationships between neutralization and ADE, the func-
tional properties of antibodies were investigated using
K562 cells: a human erythroleukemia cell line that ex-
presses high levels of the activating Fc-g receptor FcgRIIa
(CD32a) and has been used extensively to study ADE of
flaviviruses in vitro (Klein et al., 1976; Littaua et al., 1990;
Mady et al., 1991). The utility of this cell line in measuring
ADE is due in part to an inability to efficiently bind WNV in
the absence of antibody (Davis et al., 2006b). To compare
neutralization and ADE on cells capable of efficiently bind-
ing virus, studies were performed in parallel on a K562
cell line that stably expresses the attachment factor
DC-SIGNR (K562-R).
RVP-antibody complexes were created by preincuba-
tion of 19 2-fold dilutions of mAb E47 and used to infect
Raji-R, K562, and K562-R cells (Figure 3A). Analysis of in-
fections with Raji-R cells revealed the expected sigmoid-
shaped dose-response curve (red circles) as described
above. In contrast, the pattern of infection of K562 cells
in the presence of antibody approximated a biphasic dis-
tribution (green circles) characteristic of ADE (Morens
et al., 1987): the highest level of infection was observed
at an intermediate concentration of antibody (approxi-
mately 100 pM). Infection of K562-R cells (blue circles)
with RVP-antibody complexes revealed a dose-response
curve that largely overlapped with data obtained with the
parental K562 cell line. The only significant difference be-
tween these two curves was the basal level of infection ofr Inc.
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(A) Occupancy requirements for neutralization were estimated by plotting data from mAb dose-response curves (y axis) against the percentage of
accessible epitopes bound by antibody at each concentration of antibody. Percent binding was computed using the avidity data obtained by ELISA
and solving the following equation: percent bound = [Ab]/([Ab] + KD). Error bars display the standard error of triplicate infections.
(B) Percent occupancy at the EC50 and EC99. Error bars reflect the variability arising when the calculations are performed using the calculated avidity
of each antibody plus the standard deviation. This analysis was not performed for E22, as complete neutralization with this antibody is not achieved
even at the highest concentrations tested.the target cell types byWNV (0.08% versus 7.5% for K562
and K562-R cells, respectively). It is important to note that
the peak enhancement titer for E47 on K562 or K562-R
cells corresponds to the concentration of antibody close
to the EC50 on Raji-R cells, reflecting the enhanced infec-
tion of the 50% of the virions bound by antibody at a stoi-
chiometry that is not sufficient to neutralize infection. Sim-
ilar relationships were observed when neutralization and
ADE profiles of each antibody in our panel were compared
(Figures 3B–3E; see also Figures 6A–6C for E16), as well
as in a more extensive analysis of a larger panel of anti-
bodies recognizing determinants throughout the E protein
(Oliphant et al., 2006) (S.N., C. Jost, Q.X., J. Ess, M. Engle,
J. Martin, T.O., B. Graham, M.S.D., and T.C.P., unpub-
lished data).
Together, these results suggest that neutralization and
ADE are two phenomena related by the number of anti-
bodies bound to the virion irrespective of the epitope rec-
ognized. To confirm this conclusion, we investigated the
impact of reducing the number of antibodies bound to
a single determinant by manipulating the strength of the
antibody-virion interaction. Previous studies demonstrate
that a T330I mutation in DIII dramatically reduces E24
binding (Oliphant et al., 2005). Dose-response profiles ob-
tained with RVPs that incorporate this single amino acid
change reveal a shift in both the neutralization and ADE
dose-response profiles toward higher concentrations of
antibody without altering the relationship between the
two phenomena (Figure 3F as compared to Figure 3E).
Computational Approach to Determine Occupancy
Requirements for Antibody-Mediated Neutralization
As a first step toward determining the stoichiometry of an-
tibody binding during virus neutralization, we measured
the strength of the interaction between antibody and virus
particles. This allows an estimate of the percent occu-
pancy of accessible determinants on the virion for each
concentration of antibody used in our functional studies.CellAs multivalent interactions may occur during antibody
engagement and neutralization, virus particles were cap-
tured in the solid phase for use as antigen and incubated
with serial dilutions of anti-WNV antibodies under condi-
tions of antibody excess. Functional avidity of each anti-
body (AV50) was computed by curve fitting (Table 1).
Using the binding constants and concentrations of half-
maximal neutralization we calculated the fraction of ac-
cessible epitopes on the virion that are bound by antibody
when virus infection is neutralized (Klasse and Moore,
1996; Parren et al., 1998) (Figure 4A). Engagement of all
of the accessible epitopes on the virion was not required
to achieve significant levels of neutralization. For example,
at the EC50 of E16, on average less than 25% of the avail-
able epitopes are bound by antibody, and complete (99%)
neutralization occurs at nonsaturating concentrations (oc-
cupancy of 45% of the accessible epitopes). By compar-
ison, engagement of a larger fraction of the potential E49
epitopes is required to achieve neutralization, with ap-
proximately half the available epitopes engaged at the
EC50. Finally, neutralization by E9 is observed almost ex-
clusively at concentrations at which the full occupancy of
available epitopes is expected (Figure 4B).
Estimating the Occupancy Required
for Neutralization by Altering the Number
of Epitopes Present on West Nile Virions
The confidence of our computational approach for esti-
mating the antibody occupancy requirements of virus neu-
tralization is dependent in part on the accuracy of the avid-
ity constant measurements. This may be limited by the
impact of distortions in virion architecture that occur dur-
ing virus capture and the potential for heterogeneity in
the virus population with respect to particle geometry,
maturation state, and epitope accessibility in each sym-
metry environment. To provide an independent estimate,
we changed the number of available epitopes on the virion
and determined their impact on neutralization by E24.Host & Microbe 1, 135–145, April 2007 ª2007 Elsevier Inc. 139
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wild-type E proteins and a variant incorporating a single
point mutation (T332K) that abrogates the binding of E24
to WNV (Oliphant et al., 2005) (data not shown). The rela-
tive proportion of each form of the E protein on the virion
was controlled by changing the ratio of two plasmids
encoding wild-type and T332K E proteins during trans-
fection. Analogous approaches have been employed to
investigate the stoichiometry of HIV neutralization (Schon-
ning et al., 1999; Yang et al., 2005). RVPs produced using
the indicated proportions of wild-type and T332K E plas-
mids were preincubated with 2-fold dilutions of E24 mAb
and used to infect Raji-R and K562 cells (Figure 5). As ex-
pected, E24 potently neutralized RVPs composed of wild-
type E protein (EC50 of 24 pM), while RVPs composed of E
proteins with the T332K mutation were not neutralized on
Raji-R cells (Figure 5A). Reducing the proportion of wild-
type E protein in the virion significantly changed the
dose-response profile. Populations of RVPs composed
of both wild-type and T332K E proteins contained a signif-
icant proportion of virions resistant to neutralization. The
lower plateaus of the dose-response curves of ‘‘mixed’’
RVPS identified approximately 2%, 11%, 40%, and 77%
of RVPs in the resistant fraction (for the 75%, 50%,
25%, and 10% wild-type E protein RVP population, re-
spectively). The appearance of a resistant fraction as
a function of the reduction in the number of antibody-bind-
ing determinants suggests that virions in this subpopula-
tion no longer bind a sufficient number of antibodies for
neutralization. In addition, regression analysis of the frac-
tion of virus sensitive to neutralization revealed a small yet
significant (p < 0.0001) increase in the EC50 associated
with a reduction in the fraction of E24-binding sites
(EC50 of 21, 32, 42, and 62 pM for the 75%, 50%, 25%,
and 10% wild-type RVPs, respectively). This shift indi-
cates a requirement for engagement of a larger fraction
of the epitopes on the virion concomitant with the reduc-
tion in the total number of accessible sites. In agreement
with our computational prediction (Figure 4), these mixing
studies indicate that a large percentage of WNV virions
(90%) are neutralized when a relatively low percentage
of the available E24 epitopes (50%) are occupied by anti-
body. Half of the virions are neutralized when roughly 25%
of the accessible sites are bound bymAb. As E16 and E24
bind essentially the same epitope (Oliphant et al., 2005),
on mature virions only 120 E proteins are accessible to
E24, and therefore we estimate approximately 30 mAbs
are sufficient for neutralization.
Dose-response profiles of the same RVP-E24 com-
plexes on K562 cells also allowed us to determine the im-
pact of changing the number of antibody-binding sites on
ADE. As expected, enhancement of wild-type RVPs was
observed on K562, whereas ADE with E24 was not ob-
served with T332K RVPs at any concentration of antibody
tested (Figure 5B). The ADE profile for the ‘‘mixed’’ RVPs
composed of both wild-type and mutant proteins was
shifted to the right, indicating enhancement at higher anti-
body concentrations than observed with wild-type RVPs.
In addition, the breadth of the biphasic profile was signifi-140 Cell Host & Microbe 1, 135–145, April 2007 ª2007 Elseviecantly increased. Together, these changes are a conse-
quence of reducing the number of epitopes present on vi-
rions to levels that do not exceed a threshold required for
neutralization, and thus permit enhancement even at com-
plete occupancy. These experiments are an important
control for the transfection approach used to generate
the ‘‘mixed’’ particles. Had transfection of cells with mix-
tures of wild-type and mutant plasmids produced RVPs
composed entirely of wild-type or T332K protein, rather
thanmixtures of each protein species within the same par-
ticles, a reduction of the amplitude of the ADE curve, rather
than a shift to the right in the dose-response curve (as seen
in Figure 6D described below) would have been expected.
Both the computational approach and experiments
performed with mixed RVPs suggest that neutralization
by the most potent mAbs occurs at relatively low occu-
pancy of the number of accessible epitopes on the virion.
The precision of the ‘‘mixed’’ RVP analysis, however is
constrained by an inability to directly measure the distribu-
tion of wild-type and mutant E proteins in the RVP popula-
tions studied. While the approximate ratio of the two spe-
cies in the population was validated by Western blot (data
Figure 5. Impact of Manipulating the Number of Antibody-
Binding Determinants on the Neutralization Potency of mAb
E24
The T332K mutation blocks antibody recognition of a conserved neu-
tralization determinant on the upper lateral surface of DIII (Oliphant
et al., 2005). This change reduces E24 binding to WNV to levels below
the limits of detection by ELISA. RVPs incorporating varying propor-
tions of both wild-type E protein and E protein encoding the T332Kmu-
tation were produced using a modified complementation approach
and incubated with the indicated concentrations of E24.
(A) Dose-response curves of each RVP population using Raji-R cells.
Error bars display the standard error of triplicate infections, while dot-
ted lines illustrate the 95% confidence interval using nonlinear regres-
sion analysis. The fraction of RVPs resistant to E24 infection was cal-
culated as a function of the bottom of each dose-response curve.
(B) ADE of ‘‘mixed’’ RVP populations was measured on K562 cells as
described above.r Inc.
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of ADE of WNV Infection
(A–C) Dose-response curves for chE16 and
chE16 N297Q were performed on Raji-R (A),
K562 (B), and K562-R (C) cells.
(D) Analysis of ADE using mixtures of mAbs
chE16 and chE16 N297Q. Antibodies were
mixed at the indicated ratios (by mass) and in-
cubated with WNV RVPs at various concentra-
tions prior to addition to K562 cells. Infection
wasmonitored as a function of GFP expression
using flow cytometry. Error bars display the
standard error of triplicate infections (present
even when not visible due to low variation).not shown), interpretation is limited because RVPs are
analyzed as a population rather than as individual virions.
Higher resolution requires an understanding of how wild-
type and mutant proteins are distributed within the
population of individual virions and segregate within a
single particle into the different symmetry environments
of the virion.
Estimating the Stoichiometry of Antibody-
Dependent Enhancement of Infection
To estimate the stoichiometry requirements for ADE, stud-
ies were performed using two different forms of the mAb
E16 that differ with respect to their ability to interact with
Fc-g receptors. A chimeric form of mAb E16 (chE16)
was originally generated as an intermediate of a huma-
nization process and contains the mouse VH and VL
sequences and the human g1 and k constant region se-
quences (Oliphant et al., 2005). chE16 N297Q is a variant
with a single amino acid substitution that abolishes an
asparagine-linked glycosylation site essential for the inter-
action of this antibody with Fc-g receptors (Tao and Mor-
rison, 1989). Wild-type and N297Q chE16 bind and neu-
tralize WNV with identical efficiency when assayed on
BHK-21 (Oliphant et al., 2005) or Raji-R cells (Figure 6A).
In contrast, these two antibodies behave differently
when assayed on Fc-gRIIa+ K562 cells. Incubation of
RVPs with chE16, but not chE16 N297Q, enhanced infec-
tion on K562 cells (Figure 6B), illustrating the importance
of interactions between antibody and the Fc-g receptor
during ADE. When studied with K562-R cells (Figure 6C),
chE16 displayed a pattern similar to E47 (Figure 3A) char-
acterized by both neutralization and enhancement of in-
fection. In contrast, chE16 N297Q neutralized WNV RVP
infection on K562-R cells but did not support ADE.
Previous studies have observed that ADE occurs in the
presence of ‘‘subneutralizing quantities’’ of antibody or
sera (Morens et al., 1987). In agreement, our analyses of
neutralization and ADE on a single cell type suggest that
these two phenomena are related simply by differences
in the number of antibodies bound to a single virion (Fig-
ure 3). Enhancement of infection occurs once the virion is
bound by antibody with a stoichiometry that is no longerCellsufficient for neutralization.While the neutralization thresh-
old governs the upper limit of the stoichiometry of ADE, the
minimum number of antibodies capable of mediating ADE
remains to be established. To explore this, we performed
experiments in which equal concentrations of chE16 and
N297Q chE16 were mixed at different proportions and
used in dose-response experiments on K562 cells. Sur-
prisingly, a relatively large fraction of the antibodies (50%)
bound to the virion must be capable of interacting with
FcgRIIa tomediate ADE (Figure 6D). As the peak enhance-
ment titer corresponds to occupancy of approximately
25% (30 of 120 accessible sites for E16), these studies
suggest that ADE occurs efficiently when approximately
15 to 29 mAbs are bound to a virion at this epitope. En-
gagement by a single mAb does not appear to allow for
ADE. Assuming an equal distribution of mAb on the virion
surface, these studies suggest that several mAbs must be
present at the interface of the virus and cell, highlighting a
stoichiometry that is bordered at the lower end by require-
ments for stable attachment to the cell surface or cross-
linking of more than a single Fc-g receptor (Figure 6D).
DISCUSSION
In this study, we investigated the impact of the number of
antibodies bound to a particular neutralizing determinant
on the infectivity of WNV. The functional properties of an-
tibodies that recognized six partially overlapping epitopes
on DIII were characterized. Two independent approaches
suggest that, for the most potent antibodies studied, neu-
tralization was achieved upon engagement of a relatively
small fraction of the available epitopes on the virion. Rela-
tive to their strength of binding, analysis of the dose-
response curves of the three most potent antibodies
revealed that most of the virions in the population (99%)
were neutralized when an average of 55% of the epitopes
were bound by antibody. For E24, this conclusion was
supported by a second approach in which the number
of epitopes on the virion was reduced and the impact on
neutralization and ADE was examined. E24 completely
neutralized populations of RVPs that contain, on average,
half the number of wild-type epitopes. Moreover,Host & Microbe 1, 135–145, April 2007 ª2007 Elsevier Inc. 141
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achieved when an intact epitope was present on approx-
imately 25% of the E proteins.
Quantitative analysis of the stoichiometric requirements
for WNV neutralization is complicated by the heterogene-
ity of epitopes displayed on the surface of the virion. Dif-
ferences in epitope accessibility shape the occupancy re-
quirements for neutralization among antibodies that bind
distinct epitopes on DIII of the E protein and highlight
the significance of the shape and steepness of the dose-
response curve. In this context, accessibility reflects not
only differences in the solvent exposure of an epitope
on the virion, but also the dynamics of how bound anti-
bodies impact subsequent antibody-binding events on
the surface of the virion. The three most potent antibodies
displayed relatively steep dose-response curves, indicat-
ing greater neutralization per antibody molecule on the
lower portion of the sigmoidal dose-response curve.
These antibodies neutralize infection when a relatively
low fraction of the accessible epitopes is bound. By com-
parison, neutralization by antibodies that recognize epi-
topes that are predicted to be less solvent-accessible
structures exhibit relatively flat neutralization profiles and
require engagement of a larger fraction (>90%) of epi-
topes on the virion. Together, these observations are con-
sistent with a threshold requirement for neutralization. The
occupancy requirements for different antibodies reflect
a requirement to engage a larger fraction of less abundant
epitopes to reach the threshold required for neutralization.
For antibodies like E22, not all virions in the population ap-
pear to be capable of achieving this threshold, resulting
a fraction resistant to neutralization even at saturating
concentrations of antibody.
Two models for neutralization of viruses have been fa-
vored (reviewed in Burton et al., 2001; Della-Porta and
Westaway, 1978; Klasse and Sattentau, 2002). ‘‘Single
hit’’ models, based in large part upon kinetic studies, sug-
gest that virus neutralization can be achieved following
engagement by a single antibody molecule, which may
trigger conformational changes that result in a loss of
virion infectivity. Alternatively, ‘‘multiple hit’’ models re-
quire docking of multiple antibodies to a single virion,
with neutralization occurring only after the number of anti-
bodies bound to an individual virion surpasses a threshold
required for virion inactivation. Our results support amulti-
ple hit mechanism for WNV neutralization with the most
potent DIII-specific antibodies blocking infection at a rela-
tively low occupancy of the accessible epitopes. If the
overlapping epitope shared by E16, E24, and E47 is ac-
cessible on the virion at a maximum of 120 locations as
suggested (Kaufmann et al., 2006; Nybakken et al.,
2005), neutralization of half the virions occurs when an
average of 30 antibodies are bound to the virion at this lo-
cation (25% of accessible sites). As antibodies that bind
this epitope inhibit a postattachment step during virus en-
try (Nybakken et al., 2005) and are thought to directly
block fusion (Kaufmann et al., 2006), the stoichiometric re-
quirement of antibodies that bind other epitopes on the
virion, or neutralize via different mechanisms, may differ.142 Cell Host & Microbe 1, 135–145, April 2007 ª2007 ElsevieWhile the stoichiometry of antibody-mediated neutrali-
zation has been examined for several RNA and DNA vi-
ruses (reviewed in Burton et al., 2001; Klasse and Satten-
tau, 2002, and references within), no information has been
reported for enveloped viruses with icosahedral symmetry
or those with class II fusion glycoproteins. Burton and col-
leagues have suggested the stoichiometry of neutraliza-
tion reflects the number of antibodies required to ‘‘coat’’
the surface of the virion, which can be estimated as a func-
tion of the surface area of the virion (Burton et al., 2001). By
comparison, extrapolating from the reported stoichiome-
try of four different viruses, the ‘‘coating theory’’ for neu-
tralization predicts that 26 antibodies are sufficient to neu-
tralize a virion with the 50 nMdiameter of a flavivirus.While
this number is in close agreement with the estimates for
E24 reported within, we note that the binding footprint of
30 antibodies (30 3 approximately 1550 A˚2 of surface
area) at this epitope occludes a modest fraction (6%) of
the total surface area of the 50 nM diameter virion, high-
lighting the potential for steric effects associated with
the relatively large size of the intact antibody on the mech-
anism of neutralization (Nybakken et al., 2005).
An unanswered question has been whether antibodies
that promote ADE recognize unique epitopes or bind to
common viral determinants with a specific stoichiometry.
Considering ADE in the context of the stoichiometric re-
quirements for neutralization suggests criteria for defining
‘‘enhancing’’ epitopes on the virion. Our studies of over
160 mAbs suggest that, when a virion is bound by a num-
ber of antibodies that is not sufficient for neutralization,
enhancement in Fc-g receptor-expressing cells is possi-
ble irrespective of the epitope (Oliphant et al., 2006)
(T.C.P., T.O., and M.S.D., unpublished data). Not all epi-
topes on surface of the virion are equally accessible to
antibody (Oliphant et al., 2006; Stiasny et al., 2006). In
instances where the abundance of accessible epitopes
on individual virions does not exceed the threshold for
neutralization, enhancement of infection is possible even
at saturating concentrations of antibody. Enhancement
in Fc-g receptor-expressing cells of the ‘‘resistant frac-
tion’’ of E22 and several mAbs that bind epitopes in DII
was readily observed under saturating conditions (Oli-
phant et al., 2006) (S.N. and T.C.P., unpublished data).
Similarly, mutant RVPs that contain a relatively small num-
ber of E24 epitopes exhibit a fraction of virions resistant to
neutralization, a shift of the dose-response curve to the
right, and a broadening of the concentrations that pro-
mote ADE on cells bearing Fc-g receptors.
Overall, our studies have explored the quantitative rela-
tionships between antibody binding, neutralization, and
enhancement ofWNV infection. Flavivirusesmay be a par-
ticularly unique case with respect to the stoichiometry of
antibody function due to heterogeneity in epitope accessi-
bility that stems from the quasi-icosahedral nature of the
virion. The finding that antibody epitope specificity deter-
mines occupancy and neutralization will likely be relevant
to the generation of vaccines and antibody-based thera-
peutics against flaviviruses, including WNV. Antibodies
that recognize exposed neutralizing epitopes on the lateralr Inc.
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Oliphant et al., 2005) because complete neutralization
occurs at a lower occupancy, and thus, lower antibody
concentration. Based on these findings, we suggest that
vaccines against flaviviruses should be modified to target
highly accessible epitopes on E protein that elicit anti-
bodies that bind with high occupancy at low concentra-
tions for optimal protection and increased safety.
EXPERIMENTAL PROCEDURES
Cell Lines
BHK-21 cells that stably propagate a lineage II WNV subgenomic repli-
con (BHK-21WNIIrep-G/Z cells) were created by transduction of BHK-
21 (clone 15) cells with RVPs that encapsidate a replicon encoding
both GFP and a gene product conferring resistance to the zeocin an-
tibiotic (ShBle). These cells were maintained in Dulbecco’s modified
Eagle’s media (DMEM) supplemented with 10% fetal bovine serum
(FBS), Glutamax, 300 mg/ml zeocin, and a 1% penicillin/streptomycin
(PS) solution. HEK-293T cells were maintained in DMEM, 10% FBS,
and 1% PS. K562, K562-DCSIGNR, and Raji-DCSIGNR cells were
propagated in RPMI containing 10% FCS, 25 mM HEPES, and 1%
PS. All cells were cultured at 37C in 7%CO2, and suspension cultures
were split daily to maintain cells at a density of approximately 3 3 105
cells/ml and in log phase growth. All cell culture reagents were pur-
chased from Invitrogen (Carlsbad, CA).
Plasmids
Plasmids encoding the WNV prM-E and capsid structural genes have
been described previously (Pierson et al., 2006). Neutralization escape
mutations were introduced into theWNV E protein using an overlap ex-
tension PCR strategy with primers specific for the 50 and 30 end of the
prM-E gene. PCR products were introduced into a pcDNA 3.1 vector
using directional topoisomerase-mediated cloning. The sequence of
the entire prM-E gene was confirmed by sequencing.
Epitope Mapping
Epitope identification for E22 and E9 was performed using a previously
described yeast-display method. Mapping data for E16, E24, E47, and
E49 have been reported previously (Oliphant et al., 2005). Yeast ex-
pressing a random library of WNV DIII mutants were stained with Alexa
Fluor 647-conjugatedmAbs E22 and E9 to identify loss-of-bindingmu-
tants as described (Nybakken et al., 2005). Three rounds of sorting
were performed, and individual colonies were tested for loss of binding
by flow cytometry using a Becton Dickinson FACSCaliber flow cytom-
eter. Plasmid was recovered using the Zymoprep Yeast Miniprep kit
(Zymo Research, Orange, CA), transformed into DH5a competent cells
(Stratagene, La Jolla, CA), and sequenced.
Production of WNV RVPs
WNV RVPs for neutralization studies were produced by transfection of
BHK-21 WNIIrep-G/Z cells with DNA plasmids encoding the structural
genes of WNV as described previously (Pierson et al., 2006). Transfec-
tion was performed in T75 flasks using a total of 40 mg of DNA and Lip-
ofectamine 2000 (Invitrogen, Carlsbad, CA). After removal of lipid-DNA
complexes, cells were cultured in a low-glucose formulation of DMEM
containing 25 mM HEPES, 10% FBS, and 1% PS. RVPs were har-
vested at 24 and 48 hr posttransfection, filtered through a 0.22 mM fil-
ter, and frozen in aliquots at 80C. Prior to use in neutralization stud-
ies, the infectious titer of RVP stocks was measured by infection of
Raji-R cells with serial 2-fold dilutions of virus particles. Infection was
measured 2 days later by flow cytometry using a Becton Dickinson
(Franklin Lakes, NJ) FACs Calibur. RVPs used during creation of the
BHK-21 WNIIrep-G/Z cell line were produced by transfection of
HEK-293T cells with plasmids encoding the WNIIrep-G/Z replicon
and the WNV structural genes.Cell HTo produce RVPs incorporating both wild-type E proteins and a
variant encoding the T332K mutation, a modified complementation
approach was employed. BHK-21WNIIrep-G/Z cells were transfected
with a plasmid encoding WNV capsid and varying proportions (by
mass) of either wild-type prM-E or the T332K variant. To estimate
the proportion of both forms of E proteins present in the RVP popula-
tion, RVP-containing supernatants were concentrated by ultracentri-
fugation and analyzed byWestern blot using two previously character-
ized antibodies. Total E protein wasmeasured by using the DII-specific
mAb E60 (Oliphant et al., 2005, 2006), whereas the fraction of wild-type
E protein in the RVP was approximated as a function of mAb E24-
dependent signal (data not shown).
Neutralization and Enhancement of WNV RVP Infection
Neutralization studies were performed using the B-lymphoblastoic cell
line Raji, which stably expresses the c-type lectin DC-SIGNR (Raji-R).
DC-SIGNR is a tetrameric c-type lectin that promotes more efficient
WNV infection of cells via high-avidity interactions with complex or
high mannose sugars present on the envelope proteins prM and E
(Davis et al., 2006a, 2006b). Raji-R cells were selected for study
because they bind WNV avidly, facilitating studies using the small
quantities of virus particles (and thus viral antigen) required to ensure
antibody remains in excess over all of the informative points of a neu-
tralization profile.
WNV RVP stocks were diluted and incubated with mAb for 60 min at
room temperature (in a 200 ml volume). Control experiments performed
after a longer incubation (120min) resulted in similar neutralization pro-
files, suggesting that 1 hr is sufficient for the establishment of steady-
state conditions. For antibody dose-response experiment, 19 2-fold
dilutions of antibody were studied. Antibody-RVP complexes were
then added to preplated cells in triplicate (5 3 104 cells per well of
96 well plate in 300 ml total volume). Infection was measured by flow
cytometry at 48 hr postinfection. At least 53 104 events were collected
at each point. The EC50 of each antibody was predicted by nonlinear
regression analysis using a variable slope. Statistical comparisons of
the neutralization sensitivity of different RVP populations were per-
formed using the F test (GraphPad Prism 4, GraphPad Software Inc.,
San Diego CA). Appropriate RVP dilutions for neutralization studies
were established for each RVP preparation empirically. Initially, neu-
tralization studies were performed with serial dilutions of RVPs to
establish that the concentration of RVPs does not affect the observed
potency (EC50) of a given antibody. Once established and used to
characterize the potency of E16, this antibody was then used as a ref-
erence to characterize RVP stocks prior to inclusion in neutralization
studies.
Antibody Avidity Measurements
Antibody avidity was measured as described previously (Sanchez
et al., 2005). WNV subviral particles composed solely of prM and E,
or RVPs, were produced by transfection of HEK-293T cells. Twenty-
four hours after transfection, media were replaced with a low-glucose
formulation of DMEM without FBS. Virus particles were harvested
24 hr later, filtered, and captured overnight to the bottom of high-
protein binding plates under alkaline conditions. Virus particle-coated
plates were blocked and incubated in the presence of serial dilutions
of anti-WNV antibodies under conditions of antibody excess. Bound
antibody was detected using a horseradish peroxidase-conjugated
goat anti-murine kappa chain antibody followed by colormetric analy-
sis. To estimate the apparent avidity (AV50), the resulting data were fit
to both a one-site binding model and a nonlinear dose-response
method that does not assume engagement of a single uniform site
on the virus particle (allowing for cooperative binding). Both methods
yielded similar results (data not shown).
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